We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Tests to Speed Diagnosis of Lymphatic Disorders

By LabMedica International staff writers
Posted on 23 Feb 2026

Defects in the lymphatic system affect approximately one in every 3,500 newborns and can lead to severe complications, including organ failure, breathing difficulties, and life-threatening infections. More...

However, many patients wait years for an accurate diagnosis because lymphatic disorders are often misidentified or lack known genetic causes. Now, a collaborative initiative aims to accelerate diagnosis by developing comprehensive genetic tests for congenital lymphatic diseases.

The initiative, known as CLARUM (Comprehensive Lymphatic Anomaly Revealing and Understanding Genomics), is led by Columbia University Vagelos College of Physicians and Surgeons (New York, NY, USA) and supported by a two-year USD 8.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) through its LIGHT program. The goal is to identify new genetic mutations responsible for lymphatic anomalies and develop two clinical genetic panels capable of screening for germline and mosaic mutations across 73 known genes associated with primary lymphatic diseases.

CLARUM will analyze genetic data from 2,000 patients across multiple centers to discover at least 15 new causative mutations. The team will apply advanced bioinformatics tools to identify novel genes, while also using cell-based and zebrafish models to assess variants of uncertain significance. The project also aims to develop methods to detect mosaic mutations before birth, potentially preventing ineffective or harmful treatments in fetuses with cystic lymphatic malformations.

By shortening the time to genetic diagnosis from years to weeks, the project could enable faster access to FDA-approved targeted therapies. Currently, only 20% to 30% of patients with identified mutations benefit from mutation-specific treatments. Expanding the number of known genetic causes may significantly broaden treatment eligibility. By working with technology ventures programs, the team aims to commercialize the genetic panels for use across the US, increasing access beyond major urban medical centers.

“Discovering genes that cause lymphatic anomalies and using this information to create new clinical tests will not only accelerate the diagnosis of patients, but will also lead to improved treatments and, most importantly, save lives,” said associate professor Carrie Shawber, PhD, principal investigator of the CLARUM project.

Related Links:
Vagelos College of Physicians and Surgeons 


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.